Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.

Comparing R&D Priorities: Regeneron vs. Supernus

__timestampRegeneron Pharmaceuticals, Inc.Supernus Pharmaceuticals, Inc.
Wednesday, January 1, 2014127135300019586000
Thursday, January 1, 2015162057700029135000
Friday, January 1, 2016205229500042791000
Sunday, January 1, 2017207514200049577000
Monday, January 1, 2018218610000089209000
Tuesday, January 1, 2019303660000069099000
Wednesday, January 1, 2020273500000075961000
Friday, January 1, 2021290810000090467000
Saturday, January 1, 2022359250000074552000
Sunday, January 1, 2023443900000091593000
Monday, January 1, 20245132000000
Loading chart...

Unleashing insights

Innovation in Pharmaceuticals: A Tale of Two Companies

In the competitive world of pharmaceuticals, innovation is key to staying ahead. Regeneron Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. exemplify two distinct approaches to research and development (R&D) spending. Over the past decade, Regeneron has consistently prioritized innovation, with R&D expenses growing by an impressive 250% from 2014 to 2023. In contrast, Supernus has shown a more modest increase of around 370% in the same period, albeit from a much smaller base.

Regeneron's commitment to innovation is evident, with R&D spending peaking at $4.4 billion in 2023, a stark contrast to Supernus's $91.6 million. This disparity highlights Regeneron's aggressive strategy to lead in pharmaceutical advancements. As the industry evolves, these spending patterns may shape the future landscape of drug development and patient care.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025